Zobrazeno 1 - 10
of 1 014
pro vyhledávání: '"Ann‐Lii Cheng"'
Autor:
Yu-Yun Shao, Min-Shu Hsieh, Yi-Hsuan Lee, Hung-Wei Hsu, Rita Robin Wo, Han-Yu Wang, Ann-Lii Cheng, Chih-Hung Hsu
Publikováno v:
Heliyon, Vol 10, Iss 14, Pp e34289- (2024)
The anti-programmed death-ligand 1 (PD-L1) antibody is a standard therapy for advanced hepatocellular carcinoma (HCC). Tumor expression of PD-L1 can be induced upon stimulus. Because cyclin-dependent kinase 9 (CDK9) inhibition reduces the expression
Externí odkaz:
https://doaj.org/article/17d5b1d346e04280aa47dacdb32645f5
Autor:
Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, Valeriy Breder
Publikováno v:
Liver Cancer (2024)
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpo
Externí odkaz:
https://doaj.org/article/d51ee563349d44e9ad5aa1c2a8eccf42
Autor:
Tsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, Li-Chun Lu, Po-Ting Lin, Yung-Yeh Su, Wei Teng, Shiue-Wei Lai, Ren-Hua Yeh, Tsui-Mai Kao, Pei-Chang Lee, Chi-Jung Wu, Chien-Hung Chen, Chih-Hung Hsu, Shi-Ming Lin, Yi-Hsiang Huang, Li-Tzong Chen, Ann-Lii Cheng, Ying-Chun Shen
Publikováno v:
Liver Cancer (2024)
Introduction The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods Patients with advanced HCC who received
Externí odkaz:
https://doaj.org/article/982567d91e37462383001cc9dc3d4719
Autor:
Wei‐Li Ma, Ruey‐long Hong, Pei‐Jen Lou, Ming Yao, Shang‐Ju Wu, Chung‐Wu Lin, Chun‐Wei Wang, Chin‐Hao Chang, Ann‐Lii Cheng, Sung‐Hsin Kuo
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background Diffuse large B‐cell lymphoma (DLBCL) of the head‐and‐neck area primarily involves the Waldeyer ring (WR) and sinonasal area (SN). However, the differential clinical outcomes between patients with WR‐DLBCL and those with S
Externí odkaz:
https://doaj.org/article/31b9d14c5b67479aae5bf16039a43fcb
Autor:
Ming Yao, Shu‐Lang Liao, Chung‐Wu Lin, Cheng‐Ping Wang, Wei‐Li Ma, Yi‐Hsuan Wei, Jyh‐Ming Liou, I‐Jong Wang, Ann‐Lii Cheng, Sung‐Hsin Kuo
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 55-66 (2023)
Abstract Between January 2010 and December 2015, we enrolled 28 patients with stage IEI/IIE1 extragastric mucosa‐associated lymphoid tissue (MALT) lymphoma who received first‐line antibiotic treatment, after informing them about the pros and cons
Externí odkaz:
https://doaj.org/article/2e19df5fb78743f68565b33dd764ee76
Autor:
Huang-Chun Lien, Chia-Lang Hsu, Yen-Shen Lu, Tom Wei-Wu Chen, I.-Chun Chen, Yu-Chia Li, Chiun-Sheng Huang, Ann-Lii Cheng, Ching-Hung Lin
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-17 (2023)
Abstract Background Metaplastic breast carcinoma (MpBC) typically consists of carcinoma of no special type (NST) with various metaplastic components. Although previous transcriptomic and proteomic studies have reported subtype-related heterogeneity,
Externí odkaz:
https://doaj.org/article/ae460c78f1664357b2b1e5a9d7202684
Publikováno v:
Journal of the Formosan Medical Association, Vol 121, Iss 8, Pp 1371-1383 (2022)
Rapidly expanding armamentarium of systemic therapy for advanced hepatocellular carcinoma (HCC) occurred in the recent few years. Multikinase inhibitors (MKI) or targeted therapy with antiangiogenic properties have been the focus of clinical studies
Externí odkaz:
https://doaj.org/article/2d9344326e9748819904e7504c46a598
Autor:
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption
Externí odkaz:
https://doaj.org/article/6af5eea42a484415bfabf884579086db
Autor:
Anthony B. El-Khoueiry, Tim Meyer, Ann-Lii Cheng, Lorenza Rimassa, Suvajit Sen, Steven Milwee, Robin Kate Kelley, Ghassan K. Abou-Alfa
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Patients with hepatocellular carcinoma (HCC) and Child–Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progres
Externí odkaz:
https://doaj.org/article/a2e4b8e7964e4b0caa19222250819492
Autor:
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Publikováno v:
Liver Cancer (2023)
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall surviva
Externí odkaz:
https://doaj.org/article/cd768b0d783a455fbb086706dc35b886